David Szlachtycz
Overview
Explore the profile of David Szlachtycz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
4
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rezoug Z, Totten S, Szlachtycz D, Atayan A, Mohler K, Albert S, et al.
JAMA Netw Open
. 2024 Sep;
7(9):e2431427.
PMID: 39226054
Importance: Between 5% and 10% of breast cancer cases are associated with an inherited germline pathogenic or likely pathogenic variant (GPV) in a breast cancer susceptibility gene (BCSG), which could...
2.
Alsaddah S, Papadakis A, Wong N, Palma L, Szlachtycz D, Marino T, et al.
Lung Cancer
. 2023 May;
181:107247.
PMID: 37209596
Background: Somatic epidermal growth factor receptor (EGFR) pathogenic variants have been identified and are routinely tested in the molecular diagnosis of non-small cell lung cancer (NSCLC) as they represent a...
3.
Assouline S, Gasiorek J, Bergeron J, Lambert C, Culjkovic-Kraljacic B, Cocolakis E, et al.
Haematologica
. 2023 Mar;
108(11):2946-2958.
PMID: 36951168
Drug resistance underpins poor outcomes in many malignancies including refractory and relapsed acute myeloid leukemia (R/R AML). Glucuronidation is a common mechanism of drug inactivation impacting many AML therapies, e.g.,...